AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Siglinu M 50/500 Tablet SR

Prescription Icon
Prescription Required

Marketer

Inuen Healthcare Pvt Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Siglinu M 50/500 Tablet SR

Combiflex DM 50/500 extended-release tablets contain a dual-action formula managing elevated blood glucose in type 2 diabetes. This helps mitigate severe diabetic complications like vision impairment and kidney disease, potentially lowering stroke and heart attack risks. Combiflex DM 50/500 may be used independently or in conjunction with other diabetes treatments. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is personalized based on your health status, glucose levels, and current medications. Consuming it with food minimizes gastrointestinal discomfort. Consistent daily dosing at the same time maximizes effectiveness; discontinuation should only occur under physician guidance. Adherence to your prescribed diet and exercise plan is crucial for diabetes management; lifestyle significantly impacts control. Common side effects include nausea, diarrhea, vomiting, stomach upset, headache, and throat irritation. Low blood sugar (hypoglycemia) is possible, especially with concurrent insulin or sulfonylurea use; learn its symptoms and management. This medication isn't universally suitable. Inform your doctor about prior kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption before starting. Pregnant or lactating individuals require medical consultation. Interactions with other drugs are possible; disclose all medications for safety. Alcohol should be minimized due to its blood sugar-lowering effects. Kidney function and blood glucose will be monitored by your doctor throughout treatment.

Primary Ingredients of Siglinu M 50/500 Tablet SR

No text provided to rephrase.

Uses of Siglinu M 50/500 Tablet SR

Managing Type 2 Diabetes

Major Benefits of Siglinu M 50/500 Tablet SR:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Take Siglinu M 50/500 Tablet SR with a meal.

Common Side effects of Siglinu M 50/500 Tablet SR:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Siglinu M 50/500 Tablet SR:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. It's recommended to take Siglinu M 50/500 Tablet SR with a meal.

How Siglinu M 50/500 Tablet SR works:

Siglinu M 50/500 SR tablets combine sitagliptin and metformin to manage blood glucose levels. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and improves insulin sensitivity. This dual action facilitates superior glycemic control.

SAFETY ADVICE

What if you forget to take Siglinu M 50/500 Tablet SR :

Should you forget a Siglinu M 50/500 Tablet SR dose, take it immediately if you remember. Otherwise, omit the missed dose if your next dose is imminent and resume your usual dosing regimen. Never take a double dose.

Facts to Know About Siglinu M 50/500 Tablet SR

LabelValue
Developing Habits No.
Treatment Category Diabetes medication

FAQs on Siglinu M 50/500 Tablet SR

Siglinu M 50/500 SR tablets combine sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged use of Siglinu M 50/500 Tablet SR can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia and neurological issues, including tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and balance difficulties (ataxia). To mitigate these risks, supplemental vitamin B12 is recommended at least annually by some researchers.
Siglinu M 50/500 Tablet SR may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Siglinu M 50/500 Tablet SR is contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Consuming alcohol with Siglinu M 50/500 Tablet SR is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitagliptin/Metformin (like Siglinu M 50/500 Tablet SR) can cause lactic acidosis, a serious medical emergency involving high blood lactic acid levels (also called Metformin-associated lactic acidosis or MALA). This rare side effect necessitates caution in patients with kidney disease, older adults, and heavy alcohol users. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If experienced, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Siglinu M 50/500 SR tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Siglinu M 50/500 Tablet SR may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Siglinu M 50/500 Tablet SR is contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Siglinu M 50/500 Tablet SR and alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (like Siglinu M 50/500 Tablet SR) can rarely cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This risk is higher in patients with kidney problems, older adults, and heavy alcohol users. Symptoms may include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, or slow heart rate. If you experience these, stop taking Sitagliptin/Metformin and seek immediate medical attention.
Prolonged use of Siglinu M 50/500 Tablet SR can lead to vitamin B12 deficiency by hindering its absorption. This deficiency, if left unaddressed, may cause anemia, neurological issues such as numbness and tingling in extremities, weakness, urinary problems, cognitive changes, and balance difficulties (ataxia). To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Siglinu M 50/500 SR tablets combine sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18 years old.
Siglinu M 50/500 Tablet SR may cause common side effects including hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects such as lactic acidosis are also possible. Prolonged use may result in vitamin B12 deficiency.
Siglinu M 50/500 Tablet SR is contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Siglinu M 50/500 Tablet SR with alcohol is unsafe and may raise your risk of lactic acidosis.
Sitagliptin/Metformin (like Siglinu M 50/500 Tablet SR) can cause lactic acidosis, a serious, potentially fatal buildup of lactic acid in the blood (also called Metformin-associated lactic acidosis or MALA). This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin immediately and seek medical attention.
Prolonged use of Siglinu M 50/500 Tablet SR can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia and neurological issues, including numbness and tingling in the extremities, weakness, urinary problems, cognitive changes, and balance difficulties (ataxia). To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Siglinu M 50/500 Tablet S...
138
MRP 145
4% off